Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia

Cheng, Fang; Cui, Zheng; Li, Qiang; Wang, Liu; Li, Weiming

doi:10.1016/j.intimp.2023.110847

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in a small series of four Japanese patients affected by Ph’+ ALL, the brain distribution of ponatinib was also affected by ABCB1 polymorphisms [ 33 ]. Additional factors responsible for the lack of correlations between dose, pharmacokinetics, clinical outcome, and tolerability may include incomplete adherence to the prescription, a well-known phenomenon described in CML patients since the beginning of TKIs use [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia

Galimberti,

Abruzzese,

Luci

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Ponatinib may be effective in chronic myeloid leukemia (CML) patients after failure of first/second line therapies. Although its efficacy for minimum plasma concentrations (Cmin) is >21.3 ng/mL (equal to 40 nM), ponatinib may cause adverse events (AE) that require dose optimization. The present study was aimed at investigating any possible correlations among ponatinib dose, plasma concentration, molecular response (MR), and tolerability in a real-world setting. Clinical and laboratory records (including MR and drug plasma concentrations) of 32 CML patients treated with ponatinib were harvested and analyzed. Twenty-seven patients (71%) had ponatinib Cmin values > 21.3 ng/mL, but Cmin values > 10.7 ng/mL (considered efficacious in BCR-Abl unmutated patients) were achieved by 80% of the patients receiving ≥30 mg/day and 45% of the subjects treated with 15 mg/day. No significant correlations were identified among clinical efficacy, tolerability, daily dose, and plasma concentration. Notably, patients who underwent dose tapering for tolerability or safety reasons did not experience treatment failure. In a real-world setting, adjustment of ponatinib daily doses lower than those registered may maintain therapeutic efficacy while reducing the risk of vascular events and improving tolerability. Further studies are warranted to confirm the present results in a larger cohort of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia

Galimberti,

Abruzzese,

Luci

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Research Progress of Measuring Tools for Patient Medication Compliance

Jian,

Peng,

Tian

et al. 2024

JBM

View full text Add to dashboard Cite

This paper introduced the content, compilation process, reliability and validity, scoring method of the evaluation tool for patients' medication compliance at home and abroad, and reviewed the research progress of the tool. The evaluation method, dimension, scoring method, evaluation content and application scope of the tool were compared, so as to provide reference for nurses to comprehensively and accurately evaluate patients' medication status.

show abstract

Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia

Cited by 2 publications

References 25 publications

A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia

A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia

Research Progress of Measuring Tools for Patient Medication Compliance

Contact Info

Product

Resources

About